Clinical characteristics of patients with myelin oligodendrocyte glycoprotein antibodies.
Journal
Current opinion in neurology
ISSN: 1473-6551
Titre abrégé: Curr Opin Neurol
Pays: England
ID NLM: 9319162
Informations de publication
Date de publication:
19 Mar 2024
19 Mar 2024
Historique:
medline:
18
3
2024
pubmed:
18
3
2024
entrez:
18
3
2024
Statut:
aheadofprint
Résumé
The clinical landscape associated to myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) has undergone a remarkable transformation over the past two decades, primarily driven by advancements in antibody detection techniques that have enhanced both the specificity and sensitivity of assays, enabling the identification of novel clinical phenotypes. Recent pivotal research publications, comprehensive reviews from established research groups, and most notably the first proposed international criteria for MOG-Ab associated disease (MOGAD) have substantially enriched our understanding of the clinical features associated with MOG-Ab. This review presents a comprehensive overview of the clinical characteristics of patients with MOG-Ab, systematically examining each core clinical syndrome defined by the proposed international MOGAD criteria. We incorporated recent insights and discussed potential challenges in applying these criteria across diverse clinical scenarios. The proposed international MOGAD criteria provide a comprehensive, homogeneous, and specific framework for characterizing the clinical features of patients with MOG-Ab, encompassing both paediatric and adult populations. In the future, the widespread adoption of specific and reliable assays for MOG-Ab detection, complemented by the development of surrogate fluid and imaging markers, holds promise for better characterizing atypical presentations, only-cerebrospinal fluid positivity and the MOGAD "seronegative" situations.
Identifiants
pubmed: 38497310
doi: 10.1097/WCO.0000000000001265
pii: 00019052-990000000-00150
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Marignier R, Hacohen Y, Cobo-Calvo A, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 2021; 20:762–772.
Cobo-Calvo A, Vukusic S, Marignier R. Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults. Curr Opin Neurol 2019; 32:459–466.
Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 2023; 22:268–282.
Sechi E, Cacciaguerra L, Chen JJ, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol 2022; 13:885218.
Bruijstens AL, Lechner C, Flet-Berliac L, et al. E.U. paediatric MOG consortium consensus. Part 1. Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 2020; 29:2–13.
Asseyer S, Hamblin J, Messina S, et al. Prodromal headache in MOG-antibody positive optic neuritis. Mult Scler Relat Disord 2020; 40:101965.
Tajfirouz D, Padungkiatsagul T, Beres S, et al. Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder. Mult Scler 2022; 28:149–153.
Chen JJ, Sotirchos ES, Henderson AD, et al. OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and multiple sclerosis. Mult Scler Relat Disord 2022; 58:103525.
Deschamps R, Lambert J, Marignier R. The frequent sign of a rare disease or the rare sign of a frequent disease? Mult Scler Relat Disord 2022; 60:103744.
Deschamps R, Shor N, Vignal C, et al. Acute optic neuritis: what are the clues to the aetiological diagnosis in real life? Mult Scler Relat Disord 2023; 76:104764.
Deschamps R, Philibert M, Lamirel C, et al. Visual field loss and structure–function relationships in optic neuritis associated with myelin oligodendrocyte glycoprotein antibody. Mult Scler 2021; 27:855–863.
Deschamps R, Shor N, Vignal C, et al. Prospective longitudinal study on prognostic factors of visual recovery and structural change after a first episode of optic neuritis. Eur J Neurol 2022; 29:2781–2791.
Rode J, Pique J, Maarouf A, et al. Time to steroids impacts visual outcome of optic neuritis in MOGAD. J Neurol Neurosurg Psychiatry 2023; 94:309–313.
Fadda G, Flanagan EP, Cacciaguerra L, et al. Myelitis features and outcomes in CNS demyelinating disorders: comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD. Front Neurol 2022; 13:1011579.
Mariano R, Messina S, Kumar K, et al. Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease. JAMA Netw Open 2019; 2:e1912732.
Mariano R, Messina S, Roca-Fernandez A, et al. Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis. Brain 2021; 144:198–212.
Zhao-Fleming HH, Valencia Sanchez C, Sechi E, et al. CNS demyelinating attacks requiring ventilatory support with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies. Neurology 2021; 97:e1351–e1358.
Dubey D, Pittock SJ, Krecke KN, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 2019; 76:301–309.
Fadda G, Alves CA, O’Mahony J, et al. Comparison of spinal cord magnetic resonance imaging features among children with acquired demyelinating syndromes. JAMA Netw Open 2021; 4:e2128871.
Sechi E, Flanagan EP. Evaluation and management of acute myelopathy. Semin Neurol 2021; 41:511–529.
Sechi E, Krecke KN, Pittock SJ, et al. Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Mult Scler 2021; 27:303–308.
Cacciaguerra L, Redenbaugh V, Chen JJ, et al. Timing and predictors of T2-lesion resolution in patients with myelin oligodendrocyte glycoprotein antibody-associated disease. Neurology 2023; 101:e1376–e1381.
Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 2019; 15:89–102.
Cobo-Calvo A, Ruiz A, Rollot F, et al. Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol 2021; 89:30–41.
Deiva K, Cobo-Calvo A, Maurey H, et al. Risk factors for academic difficulties in children with myelin oligodendrocyte glycoprotein antibody-associated acute demyelinating syndromes. Dev Med Child Neurol 2020; 62:1075–1081.
Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013; 19:1261–1267.
Baumann M, Bartels F, Finke C, et al. E.U. paediatric MOG consortium consensus. Part 2. Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 2020; 29:14–21.
Paolilo RB, Deiva K, Neuteboom R, et al. Acute disseminated encephalomyelitis: current perspectives. Children (Basel) 2020; 7:E210.
Rossor T, Benetou C, Wright S, et al. Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis. Mult Scler 2020; 26:333–342.
Bruijstens AL, Breu M, Wendel EM, et al. E.U. paediatric MOG consortium consensus. Part 4. Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 2020; 29:32–40.
Kim S, Bang SJ, Lee JJ, Seok HY. Emerging phenotype of MOG antibody-associated disease: acute haemorrhagic leucoencephalitis. J Neurol Neurosurg Psychiatry 2023; 95:97–98.
Skarsta L, Nicoletti T, Frick K, et al. Acute haemorrhagic leucoencephalitis as clinical manifestation of MOG antibody-associated disease. J Neurol Neurosurg Psychiatry 2023; 94:583–585.
Ciron J, Biotti D, Bost C, et al. Haemorrhagic myelitis as a manifestation of MOG antibody-associated disease. J Neurol Neurosurg Psychiatry 2023; 0:1–2. jnnp-2023-332539.
Cacciaguerra L, Morris P, Tobin WO, et al. Tumefactive demyelination in MOG Ab–associated disease, multiple sclerosis, and AQP-4-IgG–positive neuromyelitis optica spectrum disorder. Neurology 2023; 100:e1418–e1432.
Chia NH, Redenbaugh V, Chen JJ, et al. Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis. Mult Scler 2023; 29:748–752.
Banks SA, Morris PP, Chen JJ, et al. Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry 2021; 92:384–390.
Xu Q, Yang X, Qiu Z, et al. Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS. Mult Scler Relat Disord 2023; 77:104797.
Ogawa R, Nakashima I, Takahashi T, et al. MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 2017; 4:e322.
Armangue T, Olivé-Cirera G, Martínez-Hernandez E, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol 2020; 19:234–246.
Budhram A, Mirian A, Le C, et al. Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. J Neurol 2019; 266:2481–2487.
Valencia-Sanchez C, Guo Y, Krecke KN, et al. Cerebral cortical encephalitis in myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol 2023; 93:297–302.
Lee WJ, Kwon YN, Kim B, et al. MOG antibody-associated encephalitis in adult: clinical phenotypes and outcomes. J Neurol Neurosurg Psychiatry 2023; 94:102–112.
Montalvo M, Khattak JF, Redenbaugh V, et al. Acute symptomatic seizures secondary to myelin oligodendrocyte glycoprotein antibody-associated disease. Epilepsia 2022; 63:3180–3191.
Vega E, Arrambide G, Olivé G, et al. Non-ADEM encephalitis in patients with myelin oligodendrocyte glycoprotein antibodies: a systematic review. Eur J Neurol 2023; 30:1515–1527.
Budhram A, Mirian A, Sharma M. Meningo-cortical manifestations of myelin oligodendrocyte glycoprotein antibody-associated disease: review of a novel clinico-radiographic spectrum. Front Neurol 2022; 13:1044642.
Gu M, Mo X, Fang Z, et al. Characteristics of aseptic meningitis-like attack—an underestimated phenotype of myelin oligodendrocyte glycoprotein antibody-associated disease. Mult Scler Relat Disord 2023; 78:104939.
Chaudhuri JR, Bagul JJ, Swathi A, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease presenting as intracranial hypertension: a case report. Neurol Neuroimmunol Neuroinflamm 2022; 9:e200020.
Lin S, Long W, Wen J, et al. Myelin oligodendrocyte glycoprotein antibody-associated aseptic meningitis without neurological parenchymal lesions: a novel phenotype. Mult Scler Relat Disord 2022; 68:104126.
Dinoto A, Licciardi NM, Reindl M, et al. Peripheral neuropathy and MOG-IgG: a clinical and neuropathological retrospective study. Mult Scler Relat Disord 2022; 68:104214.
Du Y, Xiao L, Ding Z, et al. MOGAD involving cranial neuropathies: a case report and review of literature. Brain Sci 2022; 12:1529.
Bosisio L, Gastaldi M, Inglese M, et al. Asynchronous combined central and peripheral demyelination (CCPD) in a girl with anti-MOG positivity: a case report and review of the literature. J Neuroimmunol 2023; 384:578213.
Mariotto S, Gajofatto A, Batzu L, et al. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology 2019; 93:e1867–e1872.
Carta S, Cobo Calvo A, Armangué T. Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study. Neurology 2023; 100:e1095–e1108.
Matsumoto Y, Kaneko K, Takahashi T, et al. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids. Brain 2023; 146:3938–3948.
Forcadela M, Rocchi C, San Martin D, et al. Timing of MOG-IgG testing is key to 2023 MOGAD diagnostic criteria. Neurol Neuroimmunol Neuroinflamm 2024; 11:e200183.
Abdel-Mannan O, Champsas D, Tur C, et al. Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course. J Neurol Neurosurg Psychiatry 2023; jnnp-2023-332542. doi: 10.1136/jnnp-2023-332542. [Online ahead of print].
doi: 10.1136/jnnp-2023-332542.
Kim KH, Kim SH, Park NY, et al. Validation of the International MOGAD Panel proposed criteria. Mult Scler 2023; 29:1680–1683.
Lipps P, Ayroza Galvão Ribeiro Gomes AB, Kulsvehagen L, et al. Ongoing challenges in the diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 2023; 80:1377–1379.